Type: (null)
Journal: Ca-A Cancer Journal for Clinicians
Year: 2018
Pages: 68, 178-179
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma
Distribution of the number of citations over years.